Current status of antihistamine drugs repurposing for infectious diseases

Keyphrases

• Anti-infective Agents 11%
• Antihistamines 100%
• Astemizole 11%
• Azelastine 11%
• Blood-brain Barrier 11%
• Candida 11%
• Carbinoxamine 11%
• Chlorpheniramine 11%
• Clemastine 22%
• Clinical Trials 22%
• COVID-19 22%
• Cryptococcus Spp 11%
• Desloratadine 22%
• Diphenhydramine 11%
• Doxepin 11%
• Drug Repurposing 100%
• Ebola Virus 11%
• Fluconazole 11%
• Gaps in Research 11%
• Google Scholar 11%
• Granting Agencies 11%
• H1-antihistamines 11%
• Hepatitis C Virus 11%
• Human Health 11%
• IC50 11%
• In Vitro Activity 11%
• In Vitro Assay 11%
• In Vitro Data 11%
• In Vitro Study 11%
• In Vivo Evaluation 11%
• Infectious Diseases 100%
• Influenza Virus 11%
• Inhibition Rate 11%
• Label Evaluation 11%
• Leishmania 11%
• Literature Search 22%
• Loratadine 11%
• MEDLINE 11%
• Pharmaceutical Companies 11%
• Pharmacological Data 11%
• Plasmodium 11%
• Preclinical Trials 11%
• PubMed 11%
• Repurposing 11%
• Rodents 11%
• Staphylococcus Aureus 11%
• Staphylococcus Epidermidis (S. epidermidis) 11%
• Terfenadine 11%
• Toxicological Data 11%
• Trypanosoma 11%
• Wax Moth 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Antihistaminic Agent 100%
• Antiinfective Agent 10%
• Astemizole 10%
• Azelastine 10%
• Blood-Brain Barrier 10%
• Candida 10%
• Carbinoxamine 10%
• Chlorcyclizine 20%
• Chlorphenamine 10%
• Clemastine 20%
• Clinical Trial 20%
• Desloratadine 20%
• Diphenhydramine 10%
• Doxepin 10%
• Drug Repositioning 100%
• Ebola Virus 10%
• Filobasidiella 10%
• Fluconazole 10%
• Galleria mellonella 10%
• Hepatitis C Virus 10%
• IC50 10%
• Infection 100%
• Infectious Agent 10%
• Influenza Virus 10%
• Leishmania 10%
• Loratadine 10%
• Plasmodium 10%
• Severe Acute Respiratory Syndrome 20%
• Side Effect 10%
• Staphylococcus Aureus 10%
• Staphylococcus Epidermidis 10%
• Terfenadine 10%
• Trypanosoma 10%